BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi HS, Cho S, Kim MK, Lee HJ, Moon SH, Jang HJ, Ko S. SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. Mol Cell Biochem 2017;426:1-8. [DOI: 10.1007/s11010-016-2875-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Jeong MS, Lee KW, Choi YJ, Kim YG, Hwang HH, Lee SY, Jung SE, Park SA, Lee JH, Joo YJ, Cho SG, Ko SG. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer. Int J Mol Sci 2021;22:8405. [PMID: 34445110 DOI: 10.3390/ijms22168405] [Reference Citation Analysis]
2 Choi HS, Kim YK, Yun PY. Upregulation of MDR- and EMT-Related Molecules in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Lines. Int J Mol Sci 2019;20:E3034. [PMID: 31234332 DOI: 10.3390/ijms20123034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
3 Rahimi K, Lotfabad TB, Jabeen F, Mohammad Ganji S. Cytotoxic effects of mono- and di-rhamnolipids from Pseudomonas aeruginosa MR01 on MCF-7 human breast cancer cells. Colloids Surf B Biointerfaces 2019;181:943-52. [PMID: 31382344 DOI: 10.1016/j.colsurfb.2019.06.058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
4 Ozfiliz Kilbas P, Sonmez O, Uysal-Onganer P, Coker Gurkan A, Obakan Yerlikaya P, Arisan ED. Specific c-Jun N-Terminal Kinase Inhibitor, JNK-IN-8 Suppresses Mesenchymal Profile of PTX-Resistant MCF-7 Cells through Modulating PI3K/Akt, MAPK and Wnt Signaling Pathways. Biology (Basel) 2020;9:E320. [PMID: 33019717 DOI: 10.3390/biology9100320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ashrafizadeh M, Mirzaei S, Hashemi F, Zarrabi A, Zabolian A, Saleki H, Sharifzadeh SO, Soleymani L, Daneshi S, Hushmandi K, Khan H, Kumar AP, Aref AR, Samarghandian S. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomed Pharmacother 2021;141:111824. [PMID: 34175815 DOI: 10.1016/j.biopha.2021.111824] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cheon C, Kang S, Ko Y, Kim M, Jang BH, Shin YC, Ko SG. Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol. BMJ Open 2018;8:e019502. [PMID: 30082340 DOI: 10.1136/bmjopen-2017-019502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch ME. The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer (Dove Med Press) 2017;9:495-514. [PMID: 28744157 DOI: 10.2147/BCTT.S139963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Cheon C, Ko SG. A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer. Integr Cancer Ther 2020;19:1534735420911442. [PMID: 32186413 DOI: 10.1177/1534735420911442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 Cheon C, Ko SG. Phase I study to evaluate the maximum tolerated dose of the combination of SH003 and docetaxel in patients with solid cancer: A study protocol. Medicine (Baltimore) 2020;99:e22228. [PMID: 32957363 DOI: 10.1097/MD.0000000000022228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang L, Hu C, Chao H, Wang R, Lu H, Li H, Chen H. miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1. Experimental Cell Research 2019;378:1-10. [DOI: 10.1016/j.yexcr.2019.02.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]